MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway

BACKGROUND: Sorafenib is a kinase inhibitor that is used as a first-line therapy in advanced hepatocellular carcinoma (HCC) patients. However, the existence of sorafenib resistance has limited its therapeutic effect. Through RNA sequencing, we demonstrated that miR-138-1-3p was downregulated in sora...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Tong-tong, Mou, Jie, Pan, Yao-jie, Huo, Fu-chun, Du, Wen-qi, Liang, Jia, Wang, Yang, Zhang, Lan-sheng, Pei, Dong-sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327419/
https://www.ncbi.nlm.nih.gov/pubmed/34340705
http://dx.doi.org/10.1186/s12929-021-00752-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327419/
https://www.ncbi.nlm.nih.gov/pubmed/34340705
http://dx.doi.org/10.1186/s12929-021-00752-4

Ejemplares similares